The current treatment landscape of polycycthemia vera (PV) hinges on treatments like hydroxyurea and ruxolitinib, the latter having emerged as an effective second-line therapy in patients with severe pruritis, symptomatic splenomegaly, or post-PV myelofibrosis symptoms.
Additional efforts are warranted to develop promising novel treatments for polycythemia vera (PV), said researchers of a review, highlighting a need to define the best treatment approach for the chronic myeloproliferative neoplasm.
The current treatment landscape of PV hinges on treatments like hydroxyurea (HU) and ruxolitinib, the latter having emerged as an effective second-line therapy in patients with severe pruritis, symptomatic splenomegaly, or post-PV myelofibrosis symptoms.
There are also investigational drugs being assessed in trials with the aim of reducing thrombosis events and reducing symptom burden, although much of these potential treatments have fallen short in clinical trials, wrote the researchers.
“Many emerging treatments have been evaluated in the last years, especially for HU resistant patients. Unfortunately, conclusive results are still lacking,” wrote the researchers, noting that many trials of novel treatments for PV have failed to demonstrate significant repose improvements and alleviation of symptoms. “At present, givinostat seems to be the most promising novel drug and a phase III trial is ready to start in the near future. Givinostat complete clinical trials results will be available in the next years.”
Givinostat, an oral treatment that inhibits class I and II HDACs, has been evaluated in several trials, demonstrating efficacy and tolerability among patients with PV, including a pilot phase 2A study of 29 patients with JAK2 V617F-positive MPN. Among the 12 patients with PV, the treatment demonstrated 1 complete response and 6 partial responses. There were 2 patients who discontinued treatment. Among the other 10 patients, 7 (70%) achieved phlebotomy-free status, 7 (70%) had had resolved splenomegaly, and 9 (90%) had resolved pruritus. The study showed no severe toxicities with the treatment.
Following the phase 2A study, a randomized phase 2 study of 44 patients with PV resistant to HU added givinostat 50 mg once or twice daily to HU treatment. Throughout the study, 55% of patients receiving givinostat once daily achieved responses and 50% of patients receiving givinostat twice daily achieved responses while 64% and 67% achieved pruritus control, respectively. Less than 5% of patients experienced grade 3 adverse events (AEs) and no patients experienced grade 4 AEs.
A multicenter trial confirmed the findings of the previous 2 studies, showing complete and partial responses among 45 patients receiving the treatment for a median of 4 years. The study also showed a reduction of Hct below 45% without phlebotomy and a normal spleen size in over half (56%) of patients. Similar to the phase 2 study, there were no grade 4 toxicities observed.
Reference
Benevolo G, Vassallo F, Urbino I, Giai V. Polycythemia vera (PV): Update on emerging treatment options. Ther Clin Risk Manag. 2021;17:209-221.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More